← Back to Search

Texting Intervention for Gestational Diabetes

N/A
Waitlist Available
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The patient has been diagnosed with gestational diabetes or is a patient with known diabetes and a confirmed viable pregnancy
The patient is a pregnant female 18 years of age or older
Must not have
The fetus has a chromosomal or non-chromosomal malformation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether or not a text message reminder and education system will help patients with diabetes in pregnancy better adhere to their care regimen.

Who is the study for?
This trial is for pregnant women aged 18 or older with either gestational diabetes or pre-existing diabetes and a confirmed viable single pregnancy. They must have access to a cell phone with texting capabilities. Women hospitalized for pregnancy complications or without a cell phone, as well as those carrying babies with malformations, cannot participate.
What is being tested?
The study is testing whether text message reminders and educational content can help pregnant women with diabetes better adhere to their care regimen. Participants will be randomly assigned to receive these text interventions and their adherence to the recommended care will be monitored.
What are the potential side effects?
Since this trial involves sending text messages rather than medical treatments, there are no direct physical side effects expected from participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have diabetes and am currently pregnant.
Select...
I am a pregnant woman aged 18 or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My unborn baby has been diagnosed with a genetic or structural abnormality.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
compliant diabetes care

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: TextingActive Control1 Intervention
Patients in the "Texting" group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed.
Group II: No textingActive Control1 Intervention
Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
40,838 Total Patients Enrolled
2 Trials studying Diabetes
307 Patients Enrolled for Diabetes
Dorothea Mostello, MDStudy Chair - St. Louis University
All Saints Special Care Hospital, Anderson Hospital, HSHS St. Joseph's Hospital Breese, SSM DePaul Health Center, SSM St. Mary's Health Center, Southeast Hospital, St. Louis University Hospital
Johns Hopkins University School Of Medicine (Medical School)
University Co Hlth Sci Center (Residency)
2 Previous Clinical Trials
270 Total Patients Enrolled

Media Library

Texting Clinical Trial Eligibility Overview. Trial Name: NCT03025984 — N/A
Diabetes Research Study Groups: Texting, No texting
Diabetes Clinical Trial 2023: Texting Highlights & Side Effects. Trial Name: NCT03025984 — N/A
Texting 2023 Treatment Timeline for Medical Study. Trial Name: NCT03025984 — N/A
~2 spots leftby Dec 2024